TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03048799

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency
Description: The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
Study: NCT00295594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppression
Study: NCT00858884

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Description: All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Study: NCT01720173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04333927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Patients in observation group will not receive any anti-cancer therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
Study: NCT01509131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-CS plus bisacodyl
Description: Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L PEG-ASC
Description: Patients will asked to take PEG-ASC according to labeling instructions
Study: NCT02497625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Therapeutic Alliance
Description: Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
Study: NCT01662115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Regular chewing gum
Description: Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
Study: NCT02009995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Description: All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training (AT)
Description: All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AT plus Primarily Home-Based Resistance Band Training
Description: The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time.
Study: NCT01679353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal block
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.5ml
Study: NCT01978262

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Inactivated Influenza Vaccine
Description: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
Study: NCT01548157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007 / omarco and crestor
Description: HCP1007 / Rosuvastatin plus Omega-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1007 / omarco and crestor
Description: HCP1007 / Rosuvastatin plus Omega-3
Study: NCT04103697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal cancer surgery
Description: Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal cancer surgery
Description: Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
Study: NCT03622554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA)
Description: 12 APA sessions of 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Patient Education (ETP)
Description: Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
Study: NCT00828841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 Day I every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 Day I every 21 days
Study: NCT04147650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% Voclosporin Ophthalmic Solution (VOS)
Description: 0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.10% VOS
Description: 0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.20% VOS
Description: 0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
Study: NCT01694355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT04747782

Intervention type: OTHER
Intervention: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
Description: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.

Intervention type: OTHER
Intervention: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
Description: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.

Intervention type: OTHER
Intervention: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
Description: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.

Intervention type: OTHER
Intervention: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
Description: no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
Study: NCT01306487

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Macular hole surgery
Study: NCT02376075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
Study: NCT03227796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVI-04
Description: LEVI-04 intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT01388790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT02203292

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion strategy
Description: Patients will have red blood cells transfused only if Hb \< 9.0 g/dL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Description: Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
Study: NCT01734408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alum-adjuvant 160U /0.5ml
Description: inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alum-adjuvant 320U /0.5ml
Description: inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alum-adjuvant 640U /0.5ml
Description: inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvant-free 640U /0.5ml
Description: inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo
Study: NCT01148966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
Study: NCT04487574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221
Description: Participants will receive XC221 100 mg 2 times a day during 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo 2 times a day during 14 days
Study: NCT01728532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulp Canal Sealer (Kerr)
Description: permanent obturation of the root canal space with the aid of obturating points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PA0903
Description: Sealing performed by the dentist , coronal obturation placed after the canal obturation
Study: NCT01462838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P16_37-63
Description: 100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
Study: NCT03639233

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: YESS!
Description: Web based self-management education
Study: NCT02940938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applying pulse oximeter sensor
Description: During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
Study: NCT06406556

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pegaspargase combined with concurrent radiotherapy.
Description: Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.
Study: NCT00973362

Intervention type: DEVICE
Group type: OTHER
Intervention: APTIMA HPV Assay
Description: The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).

Intervention type: DEVICE
Group type: OTHER
Intervention: APTIMA HPV Assay
Description: The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).

Intervention type: DEVICE
Group type: OTHER
Intervention: FDA-Approved HPV DNA Test
Description: A FDA-Approved HPV DNA Test is used as the comparator assay.

Intervention type: DEVICE
Group type: OTHER
Intervention: FDA-Approved HPV DNA Test
Description: A FDA-Approved HPV DNA Test is used as the comparator assay.
Study: NCT04261023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orencia 125 MG Per 1 ML Prefilled Syringe
Description: Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
Study: NCT01917513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE™ colonoscopy
Description: G-EYE™ colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study: NCT03514212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProActiveS
Description: A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.